Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High Profitability • Debt-Free Liquidity • Cash Flow Softening UTHR combines exceptional profitability, cash generation, and a debt-free balance sheet with recent margin/cash-flow moderation and elevated valuation risk.
Price Behavior
Key Price Behavior Insights: • Lower highs • Accelerating decline • Support test Support Level: $487–$490 Resistance Level: $510–$513 UTHR is in a short-term downtrend below its last-month average, with $487–$490 support worth watching for a rebound and $510–$513 as the first resistance.
Sentiment & News
Key News Insights: • FDA application acceptances • Phase III enrollment • Institutional buying United Therapeutics' regulatory and clinical advances support long-term growth despite mixed earnings, stock weakness, and CEO share sales.
AI Summary
UTHR is no longer just a defensive cash-generating specialty-biopharma franchise: investors should monitor whether Tyvaso and Remodulin erosion accelerates before 2027 FDA decisions on ralinepag and Tyvaso IPF can restore growth, making clinical, regulatory, and launch execution the key valuation drivers despite its debt-free balance sheet and strong free cash flow.
Description
United Therapeutics is a biopharmaceutical company that develops and markets therapies for chronic and life‑threatening conditions, with a primary emphasis on pulmonary hypertension and select oncology indications. Its commercial portfolio includes injectable, inhaled and oral prostacyclin‑based treatments for pulmonary arterial hypertension and an antibody therapy for high‑risk neuroblastoma, while its development pipeline comprises inhalation devices, a wearable drug pump, oral agents, gene therapy and ongoing clinical programs in related pulmonary disorders. The company maintains strategic collaborations for device and drug development and is based in Silver Spring, Maryland, where it was incorporated in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 31 | Apr 7 | UTHR | United Therapeutics Corporation | Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions. | Closed | -4.6% |
| Mar 13 | Mar 20 | UTHR | United Therapeutics Corporation | Strong near‑term setup: large capital return (up to $2B buyback and $1.5B ASR started 2026-03-09), two positive Phase 3 readouts in March (ralinepag ADVANCE OUTCOMES 2026-03-02 and nebulized Tyvaso TETON‑2 NEJM IPF data 2026-03-11), record FY2025 revenue and >40% net margin, plus ~+13.5% price move into mid‑March. Combination of active repurchases, de‑risked pipeline and technical breakout supports continued upside over the next few days, albeit with biotech volatility. | Closed | -2.2% |